Changes in Beneficial Ownership · 4
KORU Medical Systems, Inc.
KRMDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form_4.xml
Filing details
- Report period
- 2026-09-08
- Issuer
- KORU Medical Systems, Inc.
- Issuer CIK
- 0000704440
- Trading symbol
- KRMD
Reporting owner 1
- Name
- KALBERMATTEN ADAM R
- Reporting owner CIK
- 0002080271
- Relationship
- Officer
- Officer title
- Chief Commercial Officer
- Address
- C/O KORU MEDICAL SYSTEMS, INC., 100 CORPORATE DRIVE, MAHWAH, NJ, 07430
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-08 | P · Form 4 | 32,000 | A | 3.16 | 394,017 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Remarks
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.
Signature 1
- Signed
- /s/ Thomas Edward Adams - Attorney-in-Fact
- Date
- 2026-09-08
Company context
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60® and FreedomEDGE® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.